Neoleukin Therapeutics (NLTX) Competitors $15.33 -0.81 (-5.02%) As of 03/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. OPT, ORIC, MNMD, MAZE, RLAY, SION, VERV, SAGE, CGEM, and TRVIShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Opthea (OPT), ORIC Pharmaceuticals (ORIC), Mind Medicine (MindMed) (MNMD), Maze Therapeutics (MAZE), Relay Therapeutics (RLAY), Sionna Therapeutics (SION), Verve Therapeutics (VERV), Sage Therapeutics (SAGE), Cullinan Therapeutics (CGEM), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Opthea ORIC Pharmaceuticals Mind Medicine (MindMed) Maze Therapeutics Relay Therapeutics Sionna Therapeutics Verve Therapeutics Sage Therapeutics Cullinan Therapeutics Trevi Therapeutics Neoleukin Therapeutics (NASDAQ:NLTX) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations. Does the media prefer NLTX or OPT? In the previous week, Opthea had 40 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 40 mentions for Opthea and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Opthea's score of -0.41 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neoleukin Therapeutics Neutral Opthea Neutral Which has better valuation & earnings, NLTX or OPT? Neoleukin Therapeutics has higher earnings, but lower revenue than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-4.93Opthea$87.67K5,986.77-$220.24MN/AN/A Does the MarketBeat Community prefer NLTX or OPT? Neoleukin Therapeutics received 31 more outperform votes than Opthea when rated by MarketBeat users. However, 48.72% of users gave Opthea an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% OptheaOutperform Votes1948.72% Underperform Votes2051.28% Is NLTX or OPT more profitable? Opthea's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Opthea N/A N/A N/A Do analysts rate NLTX or OPT? Opthea has a consensus target price of $1.33, indicating a potential downside of 60.90%. Given Opthea's stronger consensus rating and higher probable upside, analysts plainly believe Opthea is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Which has more volatility & risk, NLTX or OPT? Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Do institutionals & insiders hold more shares of NLTX or OPT? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 3.2% of Opthea shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryOpthea beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks. Remove Ads Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.07M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-4.937.1723.3318.67Price / SalesN/A220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book1.386.396.894.23Net Income-$57.56M$142.12M$3.20B$247.15M7 Day Performance7.88%-5.06%-2.98%-2.17%1 Month Performance-10.35%-7.49%1.63%-5.68%1 Year Performance-69.88%-10.91%9.44%-0.74% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$15.33-5.0%N/A-69.9%$144.07MN/A-4.9390High Trading VolumeOPTOpthea0.6983 of 5 stars$3.41+7.2%$12.00+251.9%-17.0%$524.84M$87,666.000.008Analyst DowngradeShort Interest ↑Analyst RevisionNews CoverageGap UpORICORIC Pharmaceuticals4.0823 of 5 stars$7.37+4.8%$18.86+155.9%-55.3%$523.47MN/A-4.0580Positive NewsMNMDMind Medicine (MindMed)2.3942 of 5 stars$6.92+3.0%$25.11+262.9%-34.1%$521.55MN/A-3.0640Insider TradeAnalyst RevisionNews CoverageMAZEMaze TherapeuticsN/A$11.86+6.5%$25.67+116.4%N/A$519.20M$167.50M0.00121RLAYRelay Therapeutics2.423 of 5 stars$3.10+1.3%$19.80+538.7%-67.2%$518.74M$10.01M-1.19330News CoverageSIONSionna TherapeuticsN/A$12.10-11.6%$38.50+218.2%N/A$514.50MN/A0.0035VERVVerve Therapeutics1.8237 of 5 stars$5.78+4.1%$25.50+341.2%-60.7%$513.24M$32.33M-2.35110Analyst ForecastSAGESage Therapeutics2.9747 of 5 stars$8.21+1.4%$8.81+7.3%-55.8%$504.76M$41.24M-1.25690CGEMCullinan Therapeutics2.1598 of 5 stars$8.54+0.2%$32.86+284.7%-52.9%$499.70MN/A-3.0130TRVITrevi Therapeutics3.6333 of 5 stars$6.40-1.1%$17.56+174.4%+88.4%$491.94MN/A-14.5520Short Interest ↑ Remove Ads Related Companies and Tools Related Companies Opthea Alternatives ORIC Pharmaceuticals Alternatives Mind Medicine (MindMed) Alternatives Maze Therapeutics Alternatives Relay Therapeutics Alternatives Sionna Therapeutics Alternatives Verve Therapeutics Alternatives Sage Therapeutics Alternatives Cullinan Therapeutics Alternatives Trevi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
